psilodex.org/m/terbinafine · data v2026.10.02
Clinical data and state rules are separate facts. Both are shown; neither is a decision.
Due for review. This record was last reviewed on 2026-10-02, more than a year ago. Newer evidence or label changes may not be reflected yet.
Inhibits CYP2D6 strongly enough to make normal metabolizers behave like poor metabolizers. CYP2D6 metabolizes psilocin in vitro, but CYP2D6 genotype did not change psilocin blood levels in people, so a large effect is not expected.
No pharmacology properties of concern are listed for this record.
No provision names this medication or its class.
Colorado · checked 2026-09-30Rule check overdue · the rules may have changed sinceNo provision names this medication or its class.
Oregon · checked 2026-09-30Rule check overdue · the rules may have changed sinceNew Mexico's clinical rules (proposed 7.35.3 NMAC) are not final. No provision naming this medication has been found.
New Mexico · checked 2026-10-02Rule check overdue · the rules may have changed sinceNo condition named in state rules is linked to this medication.